Summary
Diazepam has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Chronic Pancreatitis would be drug repurposing rather than first-in-human development. This does not mean it is approved for Chronic Pancreatitis. ClinicalTrials.gov lists 5 registered trials linking Diazepam to Chronic Pancreatitis: 3 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT01318369). The largest enrolment is 220 participants (NCT05270434). Registration activity spans 2011 to 2025. No published literature item is linked to Diazepam and Chronic Pancreatitis in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Chronic Pancreatitis ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Progressive exocrine and endocrine insufficiency; spontaneous improvement possible in alcoholic CP with sustained abstinence (30-40% pain improvement); structural damage (fibrosis, calcifications) is irreversible.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 30.5 (trials 10.5, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 5 total: 0 recruiting, 0 active / not yet recruiting, 3 completed, 2 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
| Linked via biomarker / target | ALDH2 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT01318369 | Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain 2011 | completed | Phase 2 | 24 |
| NCT05270434 | Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis. 2025 | completed | Not applicable | 220 |
| NCT05289362 | Comparison of Efficacy of Basket and Balloon in the Removal of Pancreatic Duct Stones in Chronic Pancreatitis Under ERCP 2022 | completed | Not applicable | 104 |
| NCT05326542 | Comparison of Efficacy of ESWL and Laser Lithotripsy in Chronic Pancreatitis With ERCP 2022 | status unknown | Not applicable | 80 |
| NCT05261997 | Endotherapy for Painless Chronic Pancreatitis 2022 | status unknown | Not applicable | 60 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL, in this case via the biomarker or target ALDH2. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Diazepam approved for Chronic Pancreatitis?
Diazepam has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Chronic Pancreatitis would be drug repurposing rather than first-in-human development. This does not mean it is approved for Chronic Pancreatitis. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Diazepam in clinical trials for Chronic Pancreatitis?
ClinicalTrials.gov lists 5 registered trials linking Diazepam to Chronic Pancreatitis: 3 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT01318369). The largest enrolment is 220 participants (NCT05270434). Registration activity spans 2011 to 2025.
What does the evidence show for Diazepam in Chronic Pancreatitis?
Diazepam has 3 completed registered trials for Chronic Pancreatitis but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL, in this case via the biomarker or target ALDH2. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.